Plasma levels of coagulation inhibitors, fibrinolytic markers and platelet-derived growth factor-AB in patients with failed hip prosthesis

Cenni, E.; Savarino, L.; Baldini, Nicola; Rotini, Roberto; Marinelli, Alessandro; Mieti, Michele; Giunti, Armando

doi:10.1080/00016470310017956

Cited by 2 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to these more frequently studied serum markers, over 40 other serum markers were studied by only one study ( Table 3 ) ( 42 , 43 , 44 , 46 , 49 , 50 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 ).…”

Section: Resultsmentioning

confidence: 99%

Biomarkers to discriminate between aseptic loosened and stable total hip or knee arthroplasties: a systematic review

Hasan,

van Schie,

Kaptein

et al. 2024

EFORT Open Reviews

View full text Add to dashboard Cite

Background Loosening is a major cause for failure of total hip and total knee arthroplasties (THAs/TKAs). Preemptive diagnostics of asymptomatic loosening could open strategies to prevent gross loosening. A multitude of biomarkers may discriminate between loosened and stable implants, but it is unknown which have the best performance. The present systematic review aimed to assess which biomarkers have shown the most promising results in discriminating between stable and aseptic loosened THAs and TKAs. Methods PubMed, Embase, Web of Science, Cochrane Library, and Academic Search Premier were systematically searched up to January 2020 for studies including THA/TKA and biomarkers to assess loosening. Two reviewers independently screened records, extracted data, and assessed the risk of bias using the ICROMS tool to classify the quality of the studies. Results Twenty-eight (three high-quality) studies were included, reporting on a median of 48 patients (interquartile range 28–69). Serum and urine markers were evaluated in 22 and 10 studies, respectively. Tumor necrosis factor α and osteocalcin were significantly higher in loosened compared with stable implants. Urinary N-terminal telopeptide had significantly elevated levels in loosened prostheses. Conclusion Several serum and urine markers were promising in discriminating between loosened and stable implants. We recommend future studies to evaluate these biomarkers in a longitudinal fashion to assess whether progression of loosening is associated with a change in these biomarkers. In particular, high-quality studies assessing the usability of these biomarkers are needed.

show abstract

Section: Resultsmentioning

confidence: 99%

Biomarkers to discriminate between aseptic loosened and stable total hip or knee arthroplasties: a systematic review

Hasan,

van Schie,

Kaptein

et al. 2024

EFORT Open Reviews

View full text Add to dashboard Cite

show abstract

“…Previously, we have found no differences in plasma levels of PDGF-AB between patients with prosthesis loosening and presurgery patients, and between patients with prosthesis loosening and patients with fixed implants (Cenni et al 2003). In contrast, PDGF-BB plasmatic levels were lower in the prosthesis-bearing patients than in presurgery subjects.…”

Section: Discussionmentioning

confidence: 99%

Plasma levels of platelet-derived growth factor BB and transforming growth factor in patients with failed hip prostheses

et al. 2005

Self Cite

View full text Add to dashboard Cite

Background The role of growth factors in prosthesis loosening is unclear. We evaluated the levels of platelet-derived growth factor BB (PDGF-BB), transforming growth factors β1 (TGF-β1) and β2 (TGF-β2), both before and after activation, in patients with aseptic loosening of their hip prosthesis.Patients and methods 26 patients with loosened hip implants were compared with 21 patients who had stable hip prostheses, and 28 patients undergoing primary hip replacement. The plasma levels of the growth factors were analyzed by enzyme immunoassay. TGF-β1 and TGF-β2 were determined both before and after activation.Results Patients with aseptic loosening had significantly lower PDGF-BB levels than patients undergoing primary hip replacement, and significantly lower TGF-β2 levels than patients with a stable implant. Patients with stable prostheses had significantly higher TGF-β1 and TGF-β2 levels than patients undergoing primary hip replacement.Interpretation It is possible that the prosthetic implant itself causes a local increase in PDGF-BB, TGF-β1 and TGF-β2, released by osteoblasts and other cells in the microenvironment. The plasma PDGF-BB measured does not correspond to local release, which is probably due to local consumption or degradation. The consumption of PDGF-BB is low in stable implants, and TGF-β1 and TGF-β2 levels increase during bone formation. In loosening, PDGF-BB consumption is higher and causes a significant reduction in plasma levels as compared to presurgery. The formation of poor-quality bone may

show abstract

Plasma levels of coagulation inhibitors, fibrinolytic markers and platelet-derived growth factor-AB in patients with failed hip prosthesis

Cited by 2 publications

References 10 publications

Biomarkers to discriminate between aseptic loosened and stable total hip or knee arthroplasties: a systematic review

Biomarkers to discriminate between aseptic loosened and stable total hip or knee arthroplasties: a systematic review

Plasma levels of platelet-derived growth factor BB and transforming growth factor in patients with failed hip prostheses

Contact Info

Product

Resources

About